Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00092105 |
The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.
Condition | Intervention | Phase |
---|---|---|
Asthma, Bronchial Rhinitis, Allergic, Perennial |
Drug: MK0476, montelukast sodium Drug: Comparator: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Double-Blind, Randomized, Crossover Study Investigating the Clinical Effect of Montelukast in Patients With Concomitant Asthma and Allergic Rhinitis Upon Controlled Exposure to Cat Allergen |
Estimated Enrollment: | 50 |
Study Start Date: | April 2002 |
The duration of treatment is 2 weeks.
Ages Eligible for Study: | 15 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2004_024 |
Study First Received: | September 21, 2004 |
Last Updated: | November 21, 2006 |
ClinicalTrials.gov Identifier: | NCT00092105 |
Health Authority: | United States: Food and Drug Administration |
Rhinitis, Allergic |
Otorhinolaryngologic Diseases Asthma Rhinitis Leukotriene Antagonists Montelukast Lung Diseases, Obstructive Hypersensitivity |
Rhinitis, Allergic, Perennial Respiratory Tract Diseases Respiratory Tract Infections Lung Diseases Hypersensitivity, Immediate Respiratory Hypersensitivity |
Respiratory System Agents Immune System Diseases Bronchial Diseases Therapeutic Uses Hormone Antagonists |
Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents Pharmacologic Actions Nose Diseases |